Glenmark Pharmaceuticals rises on launching first triple FDC Teneligliptin with Pioglitazone and Metformin
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Glenmark Pharmaceuticals is currently trading at Rs. 415.50, up by 6.30 points or 1.54% from its previous closing of Rs. 409.20 on the BSE.
The scrip opened at Rs. 411.45 and has touched a high and low of Rs. 417.55 and Rs. 409.80 respectively. So far 3745 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 533.95 on 03-Jan-2022 and a 52 week low of Rs. 348.90 on 20-Jun-2022.
Last one week high and low of the scrip stood at Rs. 444.95 and Rs. 406.95 respectively. The current market cap of the company is Rs. 11546.32 crore.
The promoters holding in the company stood at 46.65%, while Institutions and Non-Institutions held 34.08% and 19.27% respectively.
Glenmark Pharmaceuticals has launched the first triple fixed-dose combination (FDC) Teneligliptin with Pioglitazone and Metformin in India. Teneligliptin is a widely used DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor). This FDC has been launched under the brand name Zita-PioMet, and contains Teneligliptin (20 mg) + Pioglitazone (15 mg) + Metformin (500mg/1000mg) in a sustained release (SR) formulation. This offers patients with Type 2 diabetes the convenience of once daily dosing to improve their glycemic control and achieve the targeted HbA1c within 24 weeks.
Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.
